Preparation, characterization, and in vitro release study of albendazole-encapsulated nanosize liposomes

International Journal of Nanomedicine

Volumn 5, Issue 1, 2010, Pages 101-108

  Panwar, Preety ^a   Pandey, Bhumika ^a   Lakhera, P C ^b   Singh, K P ^a  

^a G B PANT UNIVERSITY OF AGRICULTURE AND TECHNOLOGY   (India)

^b H N B GARHWAL UNIVERSITY   (India)

Author keywords

Albendazole; In vitro release; Liposomes; Nanosize; PEGylated

Indexed keywords

ALBENDAZOLE; CHOLESTEROL; LIPOSOME; MACROGOL; PHOSPHATIDYLCHOLINE;

ARTICLE; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; DRUG RELEASE; IN VITRO STUDY; NANOENCAPSULATION; NANOFABRICATION; TRANSMISSION ELECTRON MICROSCOPY; ULTRAVIOLET SPECTROPHOTOMETRY;

ALBENDAZOLE; ANTHELMINTICS; BODY FLUIDS; DELAYED-ACTION PREPARATIONS; DIFFUSION; DRUG COMPOUNDING; LIPOSOMES; NANOCAPSULES;

EID: 77951183192     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Bangham AD, Standish MM, Miller N. Cation permeability of phospholipid model membranes: effect of narcotics. Nature. 1965;208:1295-1297.
2. Anabousi S, Laue M, Lehr CM, Bakowsky U, Ehrhardt C. Assessing transferrin modification of liposomes by atomic force microscopy and transmission electron microscopy. Eur J Pharm Biopharm. 2005;60:295-303.
3. Abraham SA, Waterhouse DN, Mayer LD, Cullis PR, Madden TD, Bally MB. The liposomal formulation of doxorubicin. Methods Enzymol. 2005;391:71-97.
4. Vyas SP, Quraishi S, Gupta S, Jaganathan KS. Aerosolized liposome-based delivery of amphotericin B to alveolar macrophages. Int J Pharm. 2005;296:2-25.
5. Iinuma H, Maruyama K, Okinaga K, et al. Intracellular targeting therapy of cisplatin-encapsulated transferring-polyethyleneglycol liposome on peritoneal dissemination of gastric cancer. Int J Cancer. 2002;99:130-137.
6. Hong RJ, Tseng YL. Phase I and pharmacokinetic study of a stable, polyethylene-glycolated liposomal doxorubicin in partients with solid tumors. Cancer. 2001;91:1826-1833.
7. Oku N, Doi K, Namba Y, Okada S. Therapeutic effect of adriamycin encapsulated in long-circulating liposomes on Meth-A-sarcoma-bearing mice. Int J Cancer. 1994;58:415-419.
8. Tokudome Y, Oku N, Doi K, Namba Y, Okada S. Antitumor activity of vincristin encapsulated in glucuronide-modified long-circulating liposomes in mice bearing Meth A sarcoma. Biochim Biophys Acta. 1996;1279:70-74.
9. Allen TM, Stuart DD. Liposomal pharmacokinetics. Classical, sterically-stabilized, cationic liposomes and immunoliposomes. In: Janoff AS, editor. Liposomes: Rational design. New York, NY: Marcel Dekker, Inc; 2005. pp. 63-87.
10. Working PK, Newman MS, Stuart Y, et al. Pharmacokinetics, bio-distribution and therapeutic efficacy of doxorubicin encapsulated in STEALTH liposomes. J Liposome Res. 1994;46:667-687.
11. Newman MS, Colbern GT, Working PK, Engbers C, Amantea MA. Comparative sencapsulated in long-circulating, pegylated liposomes (SPI-077) in tumor-bearing mice. Cancer Chemother Pharmacol. 1999;43:1-7.
12. Budai L, Hajdu M, Budai M, et al. Gels and liposomes in optimized ocular drug delivery: Studies on ciprofloxacin formulations. Int J Pharm. 2007;343:34-40.
13. Vyas SP, Rawat M, Rawat A, Mahor S, Gupta PN. Pegylated protein encapsulated multivesicular liposomes: a novel approach for sustained release of Interferon α. Drug Dev Ind Pharm. 2006;32:699-707.
14. Han HD, Lee A, Hwang T, et al. Enhanced circulation time and antitumor activity of doxorubicin by comblike polymer-incorporated liposomes. J Control Release. 2007;120:161-168.
15. Davis A, Dixon H, Pawlowski ZS. Multicentre clinical trials of benzimidazole-carbamates in human cystic echinococcosis (phase 2). Bull World Health Organ. 1989;67:503-508.
16. Horton RJ. Albendazole in treatment of human cystic echinococcosis: 12 years of experience. Acta Trop. 1997;64:79-93.
17. Jung H, Medina L, Garcia L, Fuentes I, Moreno-Esparza R. Absorption studies of albendazole and some physicochemical properties of the drug and its metabolite albendazole sulphoxide. J Pharm Pharmacol. 1998;50:43-48.
18. Hardin TC, Najvar LK, Rizzo J, Fothergill AW, Rinaldi MG, Graybill JR. Discrepancy between in vitro and in vivo antifungal activity of albendazole. J Med Vet Mycol. 1998;35:153-158.
19. Ramos G, Orduna A, Garcia-Yuste M. Hydatid cyst of the lung: diagnosis and treatment. World J Surg. 2001;25:46-57.
20. Anadol D, Ozcelik U, Kiper N, Gocmen A. Treatment of hydatid disease. Paediatr Drugs. 2001;3:123-135.
21. Keshmiri M, Baharvahdat H, Fattahi SH, Davachi B, Dabiri RH, Baradaran H. Albendazole versus placebo in treatment of echinococcosis. Trans R Soc Trop Med Hyg. 2001;95:190-194.
22. Alexander M, Biren PM, Daniel TC, Owe O, Richard NZ. Rapid preparation of giant unilamellar vesicles. Proc Natl Acad Sci USA. 1996;93:11443-11447.
23. Law SL, Shih CL. Characterization of calcitonin-containing liposomes formulations for intranasal delivery. J Microencapsul. 2001;18:211-221.
24. Gulati M, Grover M, Singh M, Singh S. Study of azathioprine encapsulation into liposomes. J Microencapsul. 1998;15:485-494.
25. Zhang JA, Anyarambhatla G, Ma L, et al. Development and characterization of a novel Cremophor EL free liposome-based paclitaxel (LEPETU) formulation. Eur J Pharm Biopharm. 2005;59:177-187.
26. Woo BH, Kostanski JW, Gebrekidan S, et al. Preparation characterization and in vivo evaluation of 120-day poly (D,L-lactide) leuprolide microspheres. J Control Release. 2001;75:307-315.
27. Metselaar JM, Mastrobattista E, Storm G. Liposomes for I.V. drug targeting: Design and applications. Mini Rev Med Chem. 2002;2:319-329.
28. Henriksen I, Sande SA, Smistad G, Agren T, Karlsen J. In vitro evaluation of drug release kinetics from liposomes by fractional dialysis. Int J Pharm. 1995;119:231-238.
29. Paveli Z, Kalko Basnet N, Schubert R. Liposomal gels for vaginal drug delivery. Int J Pharm. 2001;219:139-149.
30. Song H, Zhang J, Han Z, et al. Pharmacokinetic and cytotoxic studies of pegylated liposomal daunorubicin. Cancer Chemother Pharmacol. 2006;57:591-598.